急性淋巴母細胞白血病治療市場 - 按治療（化療 [Hype-CVAD、Linker Regimen]、標靶治療）、類型（B 細胞、T 細胞）、年齡層（兒童、成人）、性別（男性、女性）、治療供應商全球預測，2024 - 2032 年

Acute Lymphoblastic Leukemia Therapeutics Market - By Therapy (Chemotherapy [Hype-CVAD, Linker Regimen], Targeted Therapy), Type (B-Cell, T-Cell), Age Group (Children, Adults), Gender (Male, Female), Treatment Providers, Global Forecast, 2024 - 2032

出版日期: 2024年03月01日 | 出版商:

Global Market Insights Inc. | 英文 203 Pages | 商品交期: 2-3個工作天內

價格

簡介目錄

由於人們越來越重視提高意識和早期診斷，急性淋巴母細胞白血病治療市場規模預計在 2024 年至 2032 年期間以 6.8% 的複合年成長率擴大。加強對急性淋巴性白血病 (ALL) 症狀和危險因子的認知活動和教育活動有助於患者及早發現。早期診斷能夠及時開始治療，從而改善患者的治療結果和存活率。醫療保健提供者和倡導團體正在積極推動篩檢計劃，導致確診病例增加。

此外，FDA 批准的新藥，包括免疫療法和基因療法，為以前未滿足的醫療需求的患者帶來了新的希望。例如，2024 年1 月，開發下一代程序化T 細胞療法的生物製藥公司Autolus Therapeutics plc 宣布，美國FDA 批准了其用於治療復發/難治性(r/r) 成人B 型患者的obecabtagene autoleucel 的急性淋巴母細胞白血病製劑許可申請。這些創新藥物高度重視提高治療效果和減少副作用，為所有患者和醫療保健提供者提供了一個有希望的途徑，進一步推動了市場擴張。

ALL 治療產業分為治療、類型、年齡層、性別、治療提供者和地區。

根據治療情況，預計 2024 年至 2032 年標靶治療領域的市場價值將產生 7% 的複合年成長率。該療法透過精確靶向癌細胞，同時保護健康組織並減少副作用，提供個人化治療方法。 Blinatumomab 和 Inotuzumab Ozogamicin 等單株抗體的突破在治療 ALL 方面顯示出顯著的療效。標靶治療也抑制對癌細胞生存至關重要的特定分子途徑，從而改善患者的預後，進一步促進其越來越多的採用。

在治療提供者方面，癌症護理中心領域的急性淋巴性白血病治療產業將從2024年到2032年實現7.1%的成長率。癌症護理中心也提供尖端治療、臨床試驗和腫瘤專家，吸引了大量尋求最佳治療結果的患者。此外，ALL 盛行率的上升以及對早期檢測和治療方案的認知不斷提高將促進該細分市場的成長。

由於醫療保健支出的增加、醫療保健設施的改善以及對白血病的認知不斷提高，亞太地區急性淋巴細胞白血病治療行業預計在 2024 年至 2032 年間將成長 7.6%。此外，該地區龐大的人口基數提供了大量的患者資源。香港每年報告約 50 例新 ALL 病例，而全國則報告 15,000 例新病例。正在進行的研究計劃預計將支持所有療法的滲透。例如，2024年1月，香港中文大學醫學院對兒童ALL進行了全州範圍的多中心研究，證明CD9蛋白與ALL患者的預後密切相關。隨著對個人化醫療和新穎治療方法的日益重視，該區域產業必將呈現強勁成長。

主要趨勢
北美洲
- 美國
- 加拿大
歐洲
- 德國
- 英國
- 法國
- 西班牙
- 義大利
- 歐洲其他地區
亞太地區
- 中國
- 日本
- 印度
- 澳洲
- 亞太地區其他地區
拉丁美洲
- 巴西
- 墨西哥
- 拉丁美洲其他地區
中東和非洲
- 南非
- 沙烏地阿拉伯
- 中東和非洲其他地區

第 11 章：公司簡介

Bristol Myer Squibb Company
Celegene Corporation
Eisai Co Ltd.
Erytech Pharma
F. Hoffmann-La Roche Ltd.
Genmab A/S
GlaxoSmithKline PLC
Novartis AG
Pfizer, Inc.
Sanofi S.A.

簡介目錄

Product Code: 8368

Acute Lymphoblastic Leukemia Therapeutics Market size is poised to expand at 6.8% CAGR during 2024-2032 due to the increasing emphasis on growing awareness and early diagnosis. Greater awareness campaigns and educational initiatives about acute lymphoblastic leukemia (ALL) symptoms and risk factors have led to earlier detection among patients. Early diagnosis enables prompt initiation of treatment for improving patient outcomes and survival rates. Healthcare providers and advocacy groups are actively promoting screening programs, leading to a higher number of diagnosed cases.

Furthermore, FDA approvals for new drugs, including immunotherapies and gene therapies are providing patients with previously unmet medical needs with new hope. For instance, in January 2024, Autolus Therapeutics plc, a biopharmaceutical firm developing next-gen programmed T-cell therapies, announced that the U.S. FDA approved its Biologics License Application for obecabtagene autoleucel in patients with relapsed/refractory (r/r) Adult B-Cell Acute Lymphoblastic Leukemia. With strong focus on enhancing treatment efficacy and reducing side effects, these innovative medicines offer promising avenues for ALL patients and healthcare providers, further propelling the market expansion.

The ALL therapeutics industry is segmented into therapy, type, age group, gender, treatment provider, and region.

Based on therapy, the market value from the targeted therapy segment is anticipated to generate 7% CAGR during 2024-2032. This therapy offers personalized treatment approaches by precisely targeting cancer cells while sparing healthy tissues and reducing side effects. Breakthroughs in monoclonal antibodies, such as Blinatumomab and Inotuzumab Ozogamicin, have shown remarkable efficacy in treating ALL. Targeted therapies also inhibit specific molecular pathways crucial for cancer cell survival for improving patient outcomes, further contributing to their increasing adoption.

In terms of treatment provider, the acute lymphoblastic leukemia therapeutics industry from the cancer care centers segment will witness 7.1% growth rate from 2024 to 2032. These specialized centers provide comprehensive care, including diagnosis, treatment, as well as ongoing support for leukemia patients. Cancer care centers also offer access to cutting-edge treatments, clinical trials, and expert oncologists, attracting a significant patient pool seeking optimal outcomes. Additionally, the rising prevalence of ALL and the increasing awareness of early detection and treatment options will boost the segment growth.

Asia Pacific acute lymphoblastic leukemia therapeutics industry is anticipated to depict a 7.6% growth rate between 2024 and 2032 due to the increasing healthcare expenditure, improving access to healthcare facilities, and rising awareness about leukemia. Additionally, the large population base in the region is providing a significant patient pool. Each year, around 50 new cases of ALL are reported in Hong Kong, with 15,000 new cases reported nationwide. The ongoing research initiatives are expected to support the penetration of ALL therapeutics. For instance, in January 2024, the Chinese University of Hong Kong Faculty of Medicine performed a statewide, multicenter research on childhood ALL and proved that the CD9 protein is strongly related to the prognosis of ALL patients. With the growing emphasis on personalized medicine and novel treatment approaches, the regional industry is set to exhibit robust growth.

Chapter 1 Methodology & Scope

1.1 Market scope & definition
1.2 Base estimates & calculations
1.3 Forecast parameters
1.4 Data collection
1.5 Data validation
1.6 Data sources
- 1.6.1 Primary
- 1.6.2 Secondary
  - 1.6.2.1 Paid sources
  - 1.6.2.2 Unpaid sources

Chapter 2 Executive Summary

2.1 Industry 360 degree synopsis

Chapter 3 Industry Insights

3.1 Industry ecosystem analysis
3.2 Industry impact forces
- 3.2.1 Growth drivers
  - 3.2.1.1 Rising prevalence of acute lymphoblastic leukemia
  - 3.2.1.2 Increasing number of product approvals
- 3.2.2 Industry pitfalls & challenges
  - 3.2.2.1 High treatment cost
  - 3.2.2.2 Adverse effects associated with the treatment
3.3 Growth potential analysis
3.4 Regulatory landscape
3.5 Porter's analysis
- 3.5.1 Supplier power
- 3.5.2 Buyer power
- 3.5.3 Threat of new entrants
- 3.5.4 Threat of substitutes
- 3.5.5 Industry rivalry
3.6 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

4.1 Introduction
4.2 Company matrix analysis
4.3 Company market share analysis
4.4 Competitive positioning matrix
4.5 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Therapy, 2018 - 2032 ($ Mn)

5.1 Key trends
5.2 Chemotherapy
- 5.2.1 Hyper - CVAD regimen
- 5.2.2 CALGB 8811 regimen
- 5.2.3 Linker regimen
- 5.2.4 Nucleoside inhibitors
- 5.2.5 Oncaspar
5.3 Targeted therapy
5.4 Radiation therapy
5.5 Stem cell transplantation
5.6 Immunotherapy

Chapter 6 Market Estimates and Forecast, By Type, 2018 - 2032 ($ Mn)

6.1 Key trends
6.2 B-cell acute lymphoblastic leukemia
6.3 T-cell acute lymphoblastic leukemia
6.4 Philadelphia chromosome

Chapter 7 Market Estimates and Forecast, By Age Group, 2018 - 2032 ($ Mn)

7.1 Key trends
7.2 Children
7.3 Adults

Chapter 8 Market Estimates and Forecast, By Gender, 2018 - 2032 ($ Mn)

8.1 Key trends
8.2 Male
8.3 Female

Chapter 9 Market Estimates and Forecast, By Treatment Providers, 2018 - 2032 ($ Mn)

9.1 Hospitals & clinics
9.2 Cancer care centers
9.3 Research and academic institutes

Chapter 10 Market Estimates and Forecast, By Region, 2018 - 2032 ($ Mn)

10.1 Key trends
10.2 North America
- 10.2.1 U.S.
- 10.2.2 Canada
10.3 Europe
- 10.3.1 Germany
- 10.3.2 UK
- 10.3.3 France
- 10.3.4 Spain
- 10.3.5 Italy
- 10.3.6 Rest of Europe
10.4 Asia Pacific
- 10.4.1 China
- 10.4.2 Japan
- 10.4.3 India
- 10.4.4 Australia
- 10.4.5 Rest of Asia Pacific
10.5 Latin America
- 10.5.1 Brazil
- 10.5.2 Mexico
- 10.5.3 Rest of Latin America
10.6 Middle East and Africa
- 10.6.1 South Africa
- 10.6.2 Saudi Arabia
- 10.6.3 Rest of Middle East and Africa